Health

Molina's 10-Q moves its two biggest Medicaid wins past the 2027 recovery the Street is pricing

The 10-Q moves the Georgia and Texas wins to late 2027 or 2028 while the Street raises targets on 2027 rates; the Florida children's contract is guided to a $1.50-per-share quarterly loss and about 700 autism providers say they are unpaid. The recovery-year revenue arrives after the recovery year.

Richard TangRichard Tangtwo-minute read
Share
Molina Healthcare wordmark and logo
1 / 6Slide 1 of 6
Molina's quarterly filing moved its Georgia and Texas Medicaid wins to late 2027 or 2028, after the recovery year the Street is pricing.

Molina−3.06% — Molina, down 3.06 percent today beat estimates this week and promised the Medicaid margin turn is coming, but its own quarterly filing moved the two biggest pieces of its 2027 growth story to 2028 1. The 10-Q filed October 22 says the Georgia and Texas Medicaid awards now start in late 2027 or 2028 because of procurement protests; the filing does not name who is protesting 1. The same week, Jefferies−2.51% — Jefferies, down 2.51 percent today raised its price target on 2027 rate data 2, yet the stock closed Friday at $209.15, down 3.5% 6.

The recovery-year revenue now arrives after the recovery year, and the one live new contract is leaking.

The filing contradicts the rally case

The Georgia award once looked near. Molina was the top scorer, the state announced its intent in December 2024, and the contract was to start July 1, 2025 1. In Texas, Molina was notified in early 2024 of the intent to award the STAR and CHIP contract, the state's Medicaid managed care for children and low-income families and its Children's Health Insurance Program 1. Both are existing Molina states, meant to add share; the prior quarter's 10-Q carried no entries on either protest 1.

That matters for the money question: management guided 2027 premium to at least $45 billion against about $42 billion this year, citing modest Medicaid growth 3. If the two pending awards stay late, the growth in that guide belongs, for another year, to whoever holds those contracts now.

Molina is shrinking Marketplace and holding Medicaid flat while it waits

  • Q3 2026
  • Q3 2025
0M5,000M10,000MMedicaidMedicareMarketplace642M
Data
Q3 2026Q3 2025
Medicaid8,199M8,015M
Medicare1,616M1,610M
Marketplace642M1,197M
Premium revenue by segment, three months ended September 30, millions of US dollars. Source: Molina Healthcare Q3 2026 earnings release, Business Wire, October 21, 2026.7

The one new contract is bleeding

Florida's program for children with complex conditions did start, on October 1, and full-year guidance absorbs a $1.50-per-share loss from it in the fourth quarter 1. CBS reported that a medical attorney representing nearly 700 applied behavior analysis providers, therapists serving children with autism, says none of them have been paid since Molina took over the claims pipe, and Florida's health agency is investigating 4. This is the implementation risk that rate math never prices.

Where the judgment lands

Molina is shrinking on purpose: $1 billion of Marketplace premium cut for 2027 and the traditional Medicare book exited 1, while work requirements may remove about 260,000 Medicaid members 5. The bull case rests on 2027 rates of about 6% against 5.5% cost trend 5.

The evidence supports a split verdict: the rate-versus-trend math supports the margin turn, and the filing shows the growth lever arrives a year late. A stock at $209.15 6 is priced on a recovery whose revenue is now delayed; the question for holders is whether the target raises survive a document that moves the growth out of the recovery year.

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Loading JEF

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    Tempus AI beat Q3, but $80 million of 2027 growth rides on a December 31 Medicare deadline

    Q3 revenue of $411.5 million beat consensus, but the quarterly letter books about $80 million of 2027 growth on a Medicare repricing that only pays if the xT conversion finishes by December 31, while the cheapest product, MRD testing, grows fastest and drags reimbursement down.

    Health

    Eli Lilly puts Foundayo at $149 a month and Zepbound at $299 on Hims & Hers and LifeMD, self-pay

    Two distribution deals in two days put Lilly's Zepbound and Foundayo on Hims & Hers and LifeMD at self-pay prices starting at $149 a month. Lilly keeps the price sheet and the margin; the platforms supply the funnel.

    Health

    Novo Nordisk's 27% profit jump is the adjusted number; the reported number fell 9%

    Novo's beat-and-raise quarter hides a flat underlying US market propped up by a temporary Medicare bridge, and a reported profit that fell 9% while the adjusted line rose 27%. The CFO who called the write-offs one-offs leaves on December 31.

    Health

    Five hospitals say Lilly cut off tens of millions in 340B discounts until they hand over patient data

    Five Massachusetts hospitals say Eli Lilly cut off tens of millions in 340B drug discounts until they surrender patient claims data to a private-equity-owned platform. Lilly calls it fraud policing, and the same gross-to-net machinery under dispute just produced a record $24.4 billion quarter.

    Health

    Retatrutide cut knee pain up to 75.8% in Phase 3, and the fine print matters

    Lilly's first pivotal data for its triple-agonist drug lands at ACR this weekend just as Novo halves Wegovy's list price. The race has split between outcomes and price, and Lilly's headline percentages were never pre-specified.

    Health

    Ambience's KLAS validation put $37,500 a year on each ER doctor; $6.69 billion Abridge sells minutes

    A KLAS validation published November 3 puts about $37,500 of extra annual productivity on each emergency physician at Memorial Hermann, the Houston-based health system, the largest per-provider dollar figure KLAS has validated to date. Abridge, marked at $6.69 billion, has published minutes saved per clinician-day and no validated dollars.

    Get the newsletter

    The day's AI and market news, in your inbox every weekday.